Histone acetylation is an important part of epigenetic regulation and has become a new hotspot in the field of tumor therapy currently. Histone acetylation levels are regulated by histone acetylase (HAT) and histone deacetylase (HDAC). Multiple myeloma (MM) is a kind of plasma cell malignancy. In recent years, HDAC has been found to be overexpressed in MM, and MM patients with HDAC overexpression have poor prognosis. Efficacy of HDAC inhibitor (HDACi) in the treatment of MM has been proved in many clinical trials. HDACi may be a promising drug against MM. This paper reviews the research status of HDACi in the treatment of MM.
